| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.67 [0.57, 0.80] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | crucial | - |
| DOR | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 5.73 [2.02, 16.27] | | > 1 | | 0% | 2 studies (2/-) | 99.9 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.43 [0.56, 3.70] | | < 1 | | 0% | 2 studies (2/-) | 22.8 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.95 [0.70, 1.29] | | < 1 | | 0% | 2 studies (2/-) | 63.4 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.56 [0.79, 3.06] | | < 1 | | 65% | 2 studies (2/-) | 9.9 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.54 [0.97, 2.44] | | < 1 | | 0% | 2 studies (2/-) | 3.3 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.36 [0.28, 6.47] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.23 [0.11, 14.04] | | < 1 | | 0% | 2 studies (2/-) | 43.5 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 11.24 [1.49, 84.76] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 5.59 [1.28, 24.37] | | < 1 | | 0% | 2 studies (2/-) | 1.1 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 5.44 [0.68, 43.24] | | < 1 | | 0% | 2 studies (2/-) | 5.6 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 9.30 [2.19, 39.39] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.81 [0.06, 10.65] | | < 1 | | 0% | 2 studies (2/-) | 56.2 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.37 [0.10, 1.43] | | < 1 | | 0% | 2 studies (2/-) | 92.4 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.38 [0.26, 21.42] | | < 1 | | 0% | 2 studies (2/-) | 22.1 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.81 [0.06, 10.65] | | < 1 | | 0% | 2 studies (2/-) | 56.2 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.28 [0.04, 2.17] | | < 1 | | 0% | 2 studies (2/-) | 88.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.23 [0.11, 14.04] | | < 1 | | 0% | 2 studies (2/-) | 43.5 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.81 [0.06, 10.65] | | < 1 | | 0% | 2 studies (2/-) | 56.2 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 2.78 [0.30, 25.42] | | < 1 | | 0% | 2 studies (2/-) | 18.4 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 5.20 [0.63, 42.56] | | < 1 | | 0% | 2 studies (2/-) | 6.3 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.59 [0.04, 9.49] | | < 1 | | 0% | 2 studies (2/-) | 64.4 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.28 [0.11, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 99.7 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.33 [0.17, 0.67] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | low | not evaluable | high | non important | - |
| Constipation AE (grade 3-4) | 1.79 [0.36, 8.92] | | < 1 | | 0% | 2 studies (2/-) | 24.0 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.81 [0.06, 10.65] | | < 1 | | 0% | 2 studies (2/-) | 56.2 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.51 [0.18, 1.42] | | < 1 | | 0% | 2 studies (2/-) | 90.2 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 6.71 [1.56, 28.94] | | < 1 | | 0% | 2 studies (2/-) | 0.5 % | low | not evaluable | high | non important | - |
| Dyspnoea AE (grade 3-4) | 0.81 [0.38, 1.74] | | < 1 | | 0% | 2 studies (2/-) | 70.1 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.96 [0.87, 4.42] | | < 1 | | 0% | 2 studies (2/-) | 5.2 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 0.66 [0.22, 1.99] | | < 1 | | 0% | 2 studies (2/-) | 76.9 % | low | not evaluable | high | non important | - |
| Nausea AE (grade 3-4) | 0.81 [0.28, 2.34] | | < 1 | | 0% | 2 studies (2/-) | 65.0 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 0.31 [0.06, 1.66] | | < 1 | | 0% | 2 studies (2/-) | 91.3 % | low | not evaluable | high | non important | - |
| Vomiting AE (grade 3-4) | 0.89 [0.31, 2.52] | | < 1 | | 0% | 2 studies (2/-) | 59.0 % | low | not evaluable | high | non important | - |
